Intellia Therapeutics (NTLA)
Market Price (6/30/2026): $16.5 | Market Cap: $2.0 BilSector: Health Care | Industry: Biotechnology
Intellia Therapeutics (NTLA)
Market Price (6/30/2026): $16.5Market Cap: $2.0 BilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -15% Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 45% Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, Targeted Therapies, Show more. | Weak multi-year price returns2Y Excs Rtn is -70%, 3Y Excs Rtn is -130% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -421 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -637% Weak revenue growthRev Chg QQuarterly Revenue Change % is -9.5% Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 109% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -549%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -550% Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 93% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -24% Significant short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 42% Key risksNTLA key risks include [1] a severe FDA clinical hold on its lead Phase 3 asset, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -15% |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 45% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, Targeted Therapies, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -70%, 3Y Excs Rtn is -130% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -421 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -637% |
| Weak revenue growthRev Chg QQuarterly Revenue Change % is -9.5% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 109% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -549%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -550% |
| Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 93% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -24% |
| Significant short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 42% |
| Key risksNTLA key risks include [1] a severe FDA clinical hold on its lead Phase 3 asset, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Intellia Therapeutics (NTLA) stock has gained about 20% since 2/28/2026 because of the following key factors:
1. Positive Phase 3 Clinical Trial Results for Lonvo-z in Hereditary Angioedema (HAE). Intellia Therapeutics announced positive topline results in April 2026 from the global Phase 3 HAELO clinical trial of lonvo-z in HAE, which were reiterated in its fiscal Q1 2026 earnings report on May 11, 2026. The trial met its primary endpoint by demonstrating an 87% reduction in attack frequency versus placebo during the six-month efficacy evaluation period (weeks 5 to 28), and all key secondary endpoints were met with statistical significance (p<0.0001). This marked the world's first Phase 3 data for an in vivo gene editing candidate, leading to the initiation of a rolling Biologics License Application (BLA) submission to the FDA with a potential U.S. launch anticipated in the first half of 2027.
2. Resolution of FDA Clinical Holds on Nex-z ATTR Trials. In March 2026, the U.S. Food and Drug Administration (FDA) removed the clinical hold on the Investigational New Drug (IND) application for the MAGNITUDE Phase 3 clinical trial of nex-z for patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM). This followed the resolution of the clinical hold on the MAGNITUDE-2 Phase 3 trial for hereditary ATTR with polyneuropathy in January 2026, allowing patient screening to resume for both pivotal studies. The lifting of these holds significantly de-risked a key part of Intellia's pipeline and allowed progression of its second lead program.
Show more
Intellia Therapeutics (NTLA) stock has gained about 20% since 2/28/2026 because of the following key factors:
1. Positive Phase 3 Clinical Trial Results for Lonvo-z in Hereditary Angioedema (HAE). Intellia Therapeutics announced positive topline results in April 2026 from the global Phase 3 HAELO clinical trial of lonvo-z in HAE, which were reiterated in its fiscal Q1 2026 earnings report on May 11, 2026. The trial met its primary endpoint by demonstrating an 87% reduction in attack frequency versus placebo during the six-month efficacy evaluation period (weeks 5 to 28), and all key secondary endpoints were met with statistical significance (p<0.0001). This marked the world's first Phase 3 data for an in vivo gene editing candidate, leading to the initiation of a rolling Biologics License Application (BLA) submission to the FDA with a potential U.S. launch anticipated in the first half of 2027.
2. Resolution of FDA Clinical Holds on Nex-z ATTR Trials. In March 2026, the U.S. Food and Drug Administration (FDA) removed the clinical hold on the Investigational New Drug (IND) application for the MAGNITUDE Phase 3 clinical trial of nex-z for patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM). This followed the resolution of the clinical hold on the MAGNITUDE-2 Phase 3 trial for hereditary ATTR with polyneuropathy in January 2026, allowing patient screening to resume for both pivotal studies. The lifting of these holds significantly de-risked a key part of Intellia's pipeline and allowed progression of its second lead program.
3. Strengthened Financial Position and Extended Cash Runway. Intellia Therapeutics enhanced its financial stability by ending fiscal Q1 2026 (March 31, 2026) with $517.2 million in cash, cash equivalents, and marketable securities. Additionally, the company completed an underwritten public offering in April 2026, generating approximately $207 million in gross proceeds. These combined resources are projected to fund the company's operations at least into 2028, extending beyond the expected U.S. commercial launch of lonvo-z.
4. Better-than-Expected Fiscal Q1 2026 Earnings. For fiscal Q1 2026, reported on May 11, 2026, Intellia Therapeutics exceeded analyst expectations. The company reported an earnings per share (EPS) loss of -$0.81, which was better than the consensus estimate of -$0.92 per share. Quarterly revenue also surpassed projections, coming in at $15.05 million against an estimated $13.81 million. The net loss for the quarter narrowed to $96.2 million compared to $114.3 million in the prior year's first quarter.
Show less
Stock Movement Drivers
Fundamental Drivers
The 20.5% change in NTLA stock from 2/28/2026 to 6/29/2026 was primarily driven by a 26.1% change in the company's P/S Multiple.| (LTM values as of) | 2282026 | 6292026 | Change |
|---|---|---|---|
| Stock Price ($) | 13.78 | 16.61 | 20.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 68 | 66 | -2.3% |
| P/S Multiple | 23.6 | 29.8 | 26.1% |
| Shares Outstanding (Mil) | 116 | 118 | -2.1% |
| Cumulative Contribution | 20.5% |
Market Drivers
2/28/2026 to 6/29/2026| Return | Correlation | |
|---|---|---|
| NTLA | 20.5% | |
| Market (SPY) | 8.3% | 44.8% |
| Sector (XLV) | 0.7% | 35.1% |
Fundamental Drivers
The 84.8% change in NTLA stock from 11/30/2025 to 6/29/2026 was primarily driven by a 72.9% change in the company's P/S Multiple.| (LTM values as of) | 11302025 | 6292026 | Change |
|---|---|---|---|
| Stock Price ($) | 8.99 | 16.61 | 84.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 58 | 66 | 14.9% |
| P/S Multiple | 17.2 | 29.8 | 72.9% |
| Shares Outstanding (Mil) | 110 | 118 | -7.0% |
| Cumulative Contribution | 84.8% |
Market Drivers
11/30/2025 to 6/29/2026| Return | Correlation | |
|---|---|---|
| NTLA | 84.8% | |
| Market (SPY) | 9.0% | 41.1% |
| Sector (XLV) | 2.8% | 28.1% |
Fundamental Drivers
The 141.8% change in NTLA stock from 5/31/2025 to 6/29/2026 was primarily driven by a 90.8% change in the company's P/S Multiple.| (LTM values as of) | 5312025 | 6292026 | Change |
|---|---|---|---|
| Stock Price ($) | 6.87 | 16.61 | 141.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 46 | 66 | 45.0% |
| P/S Multiple | 15.6 | 29.8 | 90.8% |
| Shares Outstanding (Mil) | 104 | 118 | -12.7% |
| Cumulative Contribution | 141.8% |
Market Drivers
5/31/2025 to 6/29/2026| Return | Correlation | |
|---|---|---|
| NTLA | 141.8% | |
| Market (SPY) | 27.2% | 30.8% |
| Sector (XLV) | 23.3% | 22.4% |
Fundamental Drivers
The -55.4% change in NTLA stock from 5/31/2023 to 6/29/2026 was primarily driven by a -51.3% change in the company's P/S Multiple.| (LTM values as of) | 5312023 | 6292026 | Change |
|---|---|---|---|
| Stock Price ($) | 37.26 | 16.61 | -55.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 53 | 66 | 23.6% |
| P/S Multiple | 61.2 | 29.8 | -51.3% |
| Shares Outstanding (Mil) | 88 | 118 | -25.9% |
| Cumulative Contribution | -55.4% |
Market Drivers
5/31/2023 to 6/29/2026| Return | Correlation | |
|---|---|---|
| NTLA | -55.4% | |
| Market (SPY) | 84.3% | 34.9% |
| Sector (XLV) | 32.2% | 29.0% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| NTLA Return | 117% | -70% | -13% | -62% | -23% | 86% | -69% |
| Peers Return | -18% | -24% | 20% | -31% | 26% | 12% | -27% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 7% | 96% |
Monthly Win Rates [3] | |||||||
| NTLA Win Rate | 42% | 25% | 50% | 33% | 33% | 83% | |
| Peers Win Rate | 42% | 47% | 52% | 40% | 65% | 57% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| NTLA Max Drawdown | -44% | -72% | -50% | -65% | -71% | -30% | |
| Peers Max Drawdown | -47% | -46% | -36% | -53% | -46% | -28% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: CRSP, EDIT, BEAM, VRTX, REGN. See NTLA Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 6/29/2026 (YTD)
How Low Can It Go
| Event | NTLA | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -48.9% | -18.8% |
| % Gain to Breakeven | 95.5% | 23.1% |
| Time to Breakeven | 104 days | 79 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -16.3% | -6.7% |
| % Gain to Breakeven | 19.5% | 7.1% |
| Time to Breakeven | 22 days | 31 days |
| 2020 COVID-19 Crash | ||
| % Loss | -32.6% | -33.7% |
| % Gain to Breakeven | 48.4% | 50.9% |
| Time to Breakeven | 35 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -56.2% | -19.2% |
| % Gain to Breakeven | 128.1% | 23.8% |
| Time to Breakeven | 658 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -33.1% | -3.7% |
| % Gain to Breakeven | 49.6% | 3.9% |
| Time to Breakeven | 29 days | 6 days |
In The Past
Intellia Therapeutics's stock fell -48.9% during the 2025 US Tariff Shock. Such a loss loss requires a 95.5% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | NTLA | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -48.9% | -18.8% |
| % Gain to Breakeven | 95.5% | 23.1% |
| Time to Breakeven | 104 days | 79 days |
| 2020 COVID-19 Crash | ||
| % Loss | -32.6% | -33.7% |
| % Gain to Breakeven | 48.4% | 50.9% |
| Time to Breakeven | 35 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -56.2% | -19.2% |
| % Gain to Breakeven | 128.1% | 23.8% |
| Time to Breakeven | 658 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -33.1% | -3.7% |
| % Gain to Breakeven | 49.6% | 3.9% |
| Time to Breakeven | 29 days | 6 days |
In The Past
Intellia Therapeutics's stock fell -48.9% during the 2025 US Tariff Shock. Such a loss loss requires a 95.5% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Intellia Therapeutics (NTLA)
Intellia Therapeutics (NTLA) is a pioneering genome editing company focused on developing revolutionary therapeutics using CRISPR/Cas9 technology. The company's core mission is to precisely edit genes, both inside and outside the human body, to treat and potentially cure a wide range of severe genetic and acquired diseases. By leveraging this cutting-edge gene-editing platform, Intellia aims to address the root causes of illnesses, offering potentially transformative treatments where current options may be limited or non-existent.
The company's pipeline is divided into two main approaches: "in vivo" programs and "ex vivo" programs. In vivo programs involve delivering gene-editing tools directly into the body to edit cells, with lead candidates including NTLA-2001 for transthyretin amyloidosis and NTLA-2002 for hereditary angioedema. Other in vivo efforts target liver-focused conditions such as hemophilia A and B. Ex vivo programs involve editing a patient's cells outside the body before reintroducing them; NTLA-5001, a treatment for acute myeloid leukemia, is a key ex vivo program, alongside others targeting various oncological and autoimmune disorders.
Intellia's primary market consists of patients suffering from serious genetic and acquired diseases that currently lack adequate therapeutic options. Beyond its proprietary pipeline, the company also engages in strategic collaborations with major pharmaceutical partners like Regeneron and Novartis to co-develop potential products for conditions such as hemophilia and sickle cell disease, and with SparingVision for ocular diseases. These partnerships expand the application of Intellia's CRISPR/Cas9 technology and accelerate the development of new genomic medicines, ultimately aiming to serve a broad patient population in critical need of advanced treatments.
AI Analysis | Feedback
Here are a few analogies to describe Intellia Therapeutics:
The **Moderna of gene editing.**
The **Intel for the human genome.**
AI Analysis | Feedback
- NTLA-2001: A therapeutic in clinical trials for the treatment of transthyretin amyloidosis.
- NTLA-2002: A therapeutic under development for the treatment of hereditary angioedema.
- Liver-Focused Therapeutics: A pipeline of genomic medicines targeting various liver diseases, including hemophilia A, hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency.
- NTLA-5001: A therapeutic in development for the treatment of acute myeloid leukemia.
- Engineered Cell Therapies: Proprietary programs focused on developing cell therapies to treat various oncological and autoimmune disorders.
- CRISPR/Cas9 System: Foundational genome editing technology offered as a tool.
AI Analysis | Feedback
Intellia Therapeutics (NTLA) primarily sells its research, development, and genomic medicine tools to other companies and research institutions through license and collaboration agreements. Its major customers, based on the provided description, include:
- Novartis Institutes for BioMedical Research, Inc. (part of Novartis AG, NYSE: NVS)
- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
- Ospedale San Raffaele
- SparingVision SAS
AI Analysis | Feedback
AI Analysis | Feedback
John Leonard, M.D. – President and Chief Executive Officer
John Leonard retired from his position as Chief Scientific Officer and Senior Vice President of Research and Development at AbbVie in 2013, after a 30-year career in pharmaceutical R&D. He subsequently joined Intellia Therapeutics to direct the research and development effort to translate CRISPR/Cas9 technology into therapeutics, becoming President and CEO in January 2018. During his tenure as global head of Pharmaceutical R&D at Abbott Laboratories, he oversaw the development of numerous novel therapeutics, including HIV protease inhibitors Norvir® and Kaletra®, and Humira®. Dr. Leonard serves on the Board of Directors of IQVIA (NYSE: IQV) and 3T Biosciences.
Glenn Goddard – Executive Vice President, Chief Financial Officer
Glenn Goddard joined Intellia Therapeutics in October 2018. Prior to Intellia, he served as Chief Financial Officer at Generation Bio Company, where he managed financial functions, investor relations, information technologies, and facilities. Previously, as Senior Vice President of Finance and Principal Financial Officer at Agios Pharmaceuticals, Mr. Goddard played a key role in the company's transition from an early-stage research company to a commercial-ready organization, including advancing its lead candidate through clinical trials and leading strategic financing efforts that raised over $700 million in equity financings. He also held senior-level financial management positions at Archemix, a privately held biopharmaceutical company, and ImmunoGen.
Birgit Schultes, Ph.D. – Chief Scientific Officer
Birgit Schultes oversees all platform and pipeline research activities at Intellia Therapeutics, encompassing both in vivo and ex vivo (engineered cell therapy) programs. With over two decades of experience in the biotechnology and pharmaceutical industry, she brings extensive expertise in immunology and cell therapy to Intellia. Dr. Schultes manages a multidisciplinary team focused on leveraging CRISPR gene editing and other core technologies to develop new product candidates.
David Lebwohl, M.D. – Executive Vice President, Chief Medical Officer
David Lebwohl joined Intellia Therapeutics as Executive Vice President and Chief Medical Officer in April 2020. His career spans three decades in the biopharmaceutical industry, successfully guiding novel medicines through all phases of clinical trials and global regulatory approvals. Before joining Intellia, Dr. Lebwohl was Chief Medical Officer at Semma Therapeutics, Inc., which was acquired by Vertex Pharmaceuticals Inc., in October 2019. Prior to Semma, he held numerous senior-level drug development leadership positions at Novartis Pharmaceuticals Inc., where he was responsible for developing the breakthrough CAR-T therapy Kymriah® and the multi-indication blockbuster Afinitor®. Earlier in his career, he worked in oncology clinical development at Bristol-Myers Squibb, Inc.
AI Analysis | Feedback
Clinical Trial Setbacks and Safety Concerns (Platform-level Liver Risk)
Intellia Therapeutics faces significant risk from clinical trial failures and safety concerns, which are particularly pronounced for its gene-editing therapies. The company experienced a "worst-case outcome" with the death of a study participant in a trial for Nex-z (formerly NTLA-2001), a gene-editing treatment for transthyretin amyloidosis (ATTR). This event led to a clinical hold on its pivotal MAGNITUDE Phase 3 trial for NTLA-2001. While the U.S. Food and Drug Administration (FDA) has since lifted the clinical hold on the MAGNITUDE Phase 3 trial for nexiguran ziclumeran, allowing patient enrollment to resume under enhanced liver safety monitoring, the separate MAGNITUDE cardiomyopathy trial remains on hold, indicating persistent concerns. Furthermore, there is an overarching concern about a "platform-level liver risk" because both of Intellia's lead therapeutic candidates utilize in vivo liver editing, suggesting potential systemic issues with their lipid nanoparticle (LNP) delivery system for liver-directed therapies. Gene-editing technologies, including CRISPR, inherently carry risks of off-target edits, unintended genetic changes, and unpredictable immune responses, which can lead to severe adverse effects and have historically resulted in patient deaths in gene therapy trials.Regulatory Challenges and Commercial Viability
The biopharmaceutical industry, especially in the cutting-edge field of gene editing, is subject to extensive and stringent regulatory oversight. Delays or failures in obtaining the necessary regulatory approvals for its product candidates could severely impede Intellia's business prospects. The existing regulatory framework, largely developed for small molecule drugs, is often not well-suited for the unique complexities and rapid pace of innovation in CRISPR-based therapies, creating additional hurdles for approval. Moreover, even if Intellia's programs achieve regulatory approval, the company faces significant challenges in commercial adoption. Its lead programs for ATTR and hereditary angioedema (HAE) would enter markets with existing, effective, and entrenched competitive treatments, which could make it difficult to gain market share and achieve commercial success.Financial Sustainability and High Burn Rate
Intellia Therapeutics has consistently incurred net losses since its inception and projects this trend to continue in the near future, indicating that its long-term financial viability is contingent upon the successful development and commercialization of its products. The company operates with a high cash burn rate, and while it had an estimated cash runway into mid-2027 as of late 2025, the substantial costs associated with advancing clinical trials and preparing for commercialization are expected to escalate spending, potentially necessitating further capital raises and leading to equity dilution for existing shareholders. To manage its financial resources, Intellia has previously resorted to layoffs and cuts in its research programs to prioritize its most advanced experimental medicines.AI Analysis | Feedback
The emergence and maturation of next-generation gene editing technologies, such as prime editing and base editing, which offer potentially superior precision and safety profiles compared to the traditional CRISPR/Cas9 system that Intellia Therapeutics primarily utilizes.
AI Analysis | Feedback
Intellia Therapeutics (NTLA) focuses on developing therapeutics for various genetic conditions. The addressable markets for their main product candidates are substantial globally and in the U.S.
In Vivo Programs
- Transthyretin Amyloidosis (ATTR): The global transthyretin amyloidosis treatment market size was estimated at USD 6.64 billion in 2024 and is projected to reach USD 16.53 billion by 2030, exhibiting a Compound Annual Growth Rate (CAGR) of 13.9% from 2025 to 2030. North America held the largest revenue share in 2024. Other estimates place the global market at USD 7.7 billion in 2025, projected to grow to USD 25.37 billion by 2034 with a CAGR of 14.16%.
- Hereditary Angioedema (HAE): The global hereditary angioedema treatment market size was valued at USD 7.64 billion in 2026 and is projected to reach USD 27.06 billion by 2034, exhibiting a CAGR of 17.12%. North America dominated this market with a 90.66% share in 2025. The U.S. market size was approximately USD 2,000 million in 2023.
- Hemophilia A: The global hemophilia A treatment market size was valued at US$10,438.3 million in 2024 and is estimated to grow to US$15,465.7 million by 2030, with a CAGR of 6.8%. North America was the largest revenue-generating market in 2024. Another source estimates the global market at USD 12.8 billion in 2021, projected to reach USD 26.9 billion by 2031.
- Hemophilia B: The global hemophilia B market size in 2023 was approximately USD 3,400 million across the 7 major markets (7MM). The United States accounted for the highest market size at around USD 2 billion in 2023. The global hemophilia B market size was valued at US$ 2,956.0 million in 2024 and is estimated to grow to US$ 4,362.0 million by 2030.
- Hyperoxaluria Type 1: The global primary hyperoxaluria treatment market reached US$ 168.96 million in 2023 and is expected to reach US$ 365.49 million by 2031, growing at a CAGR of 9.8%. Europe is expected to dominate the market with a 39.6% share. Other estimates indicate the global market size at USD 19.61 Million in 2025, projected to grow to USD 28.20 Million by 2035.
- Alpha-1 Antitrypsin Deficiency (AATD): The global alpha-1 antitrypsin deficiency disease treatment market size accounted for USD 2.6 billion in 2023 and is expected to grow at a 10.1% CAGR from 2024 to 2032. The market size in the 7MM was around USD 830 million in 2023, with the United States accounting for approximately 84% of this market. The global AATD market is projected to grow from USD 3.8 billion in 2025 to USD 12.7 billion by 2035.
Ex Vivo Programs
- Acute Myeloid Leukemia (AML): The global acute myeloid leukemia treatment market size was estimated at USD 3.47 billion in 2024 and is projected to reach USD 6.29 billion by 2030, growing at a CAGR of 10.6%. North America dominated this market with a 37.6% share in 2024. Other sources estimate the global market at USD 3.87 billion in 2025, projected to reach around USD 10.64 billion by 2035.
- Sickle Cell Disease (SCD): The global sickle cell disease treatment market size was valued at USD 4.03 Billion in 2024 and is expected to reach USD 13.06 Billion by 2033, exhibiting a CAGR of 13.26% from 2025-2033. North America holds a significant market share of around 38.7% in 2024. Another report indicates the global market size reached USD 4.73 billion in 2026 and is projected to reach USD 20.47 billion by 2034.
Proprietary Programs
- Ocular Diseases: The global ophthalmic disease therapeutics market size was valued at USD 35.54 Billion in 2024 and is poised to grow to USD 60.56 Billion by 2033, at a CAGR of 6.1%. In terms of revenue, North America accounted for a leading share in 2023, with a valuation of US$14 billion. The global ophthalmology market size is valued at USD 81.72 billion in 2025 and is predicted to increase to approximately USD 144.04 billion by 2034.
AI Analysis | Feedback
Intellia Therapeutics (NTLA) is poised for significant revenue growth over the next 2-3 years, driven primarily by the anticipated commercialization of its lead gene-editing therapies and continued progress in its strategic collaborations.
1. Commercial Launch of NTLA-2002 for Hereditary Angioedema (HAE)
The most immediate and significant driver of future revenue growth for Intellia is the expected U.S. commercial launch of NTLA-2002 (also known as lonvo-z) for hereditary angioedema (HAE). Intellia anticipates submitting a Biologics License Application (BLA) for NTLA-2002 in the second half of 2026, with a potential U.S. launch in the first half of 2027. This CRISPR-based therapy is designed as a single-dose treatment to inactivate the KLKB1 gene in the liver, aiming for lifelong control of HAE attacks. Strong patient and physician interest has been observed, with market research indicating that a high percentage of surveyed HAE patients would consider using a gene-editing therapy matching lonvo-z's profile.
2. Advancement of NTLA-2001 for Transthyretin (ATTR) Amyloidosis
Another crucial driver is the ongoing development and potential future commercialization of NTLA-2001 (also referred to as nex-z) for transthyretin (ATTR) amyloidosis. This program is being developed in collaboration with Regeneron Pharmaceuticals, Inc., with Intellia leading its development and commercialization. While the program has experienced some clinical holds, the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the MAGNITUDE-2 Phase 3 trial for hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN) and the MAGNITUDE Phase 3 trial for ATTR-CM, albeit with enhanced safety measures for the latter. Intellia aims to complete enrollment in MAGNITUDE-2 in the second half of 2026 and anticipates a potential BLA filing for ATTRv-PN by early 2028. Successful progression and eventual approval of NTLA-2001 for these indications are expected to be significant revenue contributors, with some analysts forecasting it could generate substantial annual revenue.
3. Collaboration and Milestone Payments
Intellia's revenue over the next 2-3 years will continue to be bolstered by its strategic collaboration agreements. The company currently generates revenue from upfront payments, research funding, and milestone payments associated with hitting specific development or regulatory goals. Notably, the collaboration with Regeneron Pharmaceuticals, Inc., for programs like NTLA-2001, provides cost reimbursements and milestone opportunities. Although a recent termination of a license and collaboration agreement with SparingVision SAS contributed to collaboration revenue in Q4 2025, ongoing and new partnerships, and the achievement of clinical and regulatory milestones within these collaborations, will be important for sustained revenue growth.
AI Analysis | Feedback
Share Issuance
- In July 2021, Intellia Therapeutics completed a public offering of 4,758,620 shares of common stock, generating net proceeds of approximately $648.3 million.
- The company raised approximately $114.5 million in net equity proceeds during Q3 2025 through its 'At the Market' (ATM) program.
- Annual issuances of capital stock include $582.96 million in 2021, $130.32 million in 2022, $185.75 million in 2023, and $131.49 million in 2024.
Inbound Investments
- During the third quarter of 2021, Intellia entered into a joint venture with Cellex Cell Professionals GmbH and Blackstone Life Sciences Advisors L.L.C. to establish a new CAR-T cell therapy company, in which Intellia held a 33.33% investment share.
- In February 2022, the company executed a licensing and collaboration agreement with ONK Therapeutics Ltd. to expand its product pipeline.
- Collaboration revenue for Q1 2025 was $16.6 million, a decrease from $28.9 million in Q1 2024, contributing to an expected total of approximately $57.69 million in collaboration revenue for the full 2025 fiscal year.
Outbound Investments
- In February 2022, Intellia acquired Rewrite Therapeutics, Inc., which subsequently merged into Intellia in September 2022.
- In February 2023, Intellia paid Rewrite Holders $25.0 million in research milestone obligations through a mixture of cash and 567,045 shares of common stock.
- On February 14, 2024, Intellia entered into a license, collaboration, and option agreement with ReCode Therapeutics, Inc.
Capital Expenditures
- Intellia's capital expenditures were $6.17 million in 2021, peaked at $10 million in 2022, and were $6.23 million in 2023 and $6.79 million in 2024.
- The latest reported capital expenditure for the last twelve months (as of November 3, 2025) was $3.83 million.
- In 2021, the company entered into a lease agreement to build a GMP manufacturing facility to support the production of its CRISPR-based therapies.
Latest Trefis Analyses
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 45.65 |
| Mkt Cap | 4.5 |
| Rev LTM | 115 |
| Op Inc LTM | -230 |
| FCF LTM | -252 |
| FCF 3Y Avg | -235 |
| CFO LTM | -252 |
| CFO 3Y Avg | -226 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 9.0% |
| Rev Chg 3Y Avg | 10.0% |
| Rev Chg Q | 7.8% |
| QoQ Delta Rev Chg LTM | 1.8% |
| Op Inc Chg LTM | 18.0% |
| Op Inc Chg 3Y Avg | -3.8% |
| Op Mgn LTM | -228.3% |
| Op Mgn 3Y Avg | -338.3% |
| QoQ Delta Op Mgn LTM | 15.1% |
| CFO/Rev LTM | -294.3% |
| CFO/Rev 3Y Avg | -328.6% |
| FCF/Rev LTM | -299.3% |
| FCF/Rev 3Y Avg | -338.6% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 4.5 |
| P/S | 16.2 |
| P/Op Inc | -4.1 |
| P/EBIT | -3.8 |
| P/E | -3.9 |
| P/CFO | -3.8 |
| Total Yield | -6.2% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -11.0% |
| D/E | 0.0 |
| Net D/E | -0.2 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 4.5% |
| 3M Rtn | 34.8% |
| 6M Rtn | 17.1% |
| 12M Rtn | 31.1% |
| 3Y Rtn | -5.5% |
| 1M Excs Rtn | 5.7% |
| 3M Excs Rtn | 11.9% |
| 6M Excs Rtn | 8.7% |
| 12M Excs Rtn | 15.3% |
| 3Y Excs Rtn | -79.5% |
Comparison Analyses
Price Behavior
| Market Price | $16.61 | |
| Market Cap ($ Bil) | 2.0 | |
| First Trading Date | 05/06/2016 | |
| Distance from 52W High | -40.6% | |
| 50 Days | 200 Days | |
| DMA Price | $13.97 | $13.59 |
| DMA Trend | up | up |
| Distance from DMA | 18.9% | 22.2% |
| 3M | 1YR | |
| Volatility | 88.1% | 99.5% |
| Downside Capture | 183.65 | 254.68 |
| Upside Capture | 205.42 | 263.52 |
| Correlation (SPY) | 42.9% | 30.9% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.18 | 1.54 | 2.16 | 2.33 | 2.29 | 1.78 |
| Up Beta | 0.15 | 2.52 | 2.44 | 2.47 | 1.50 | 1.30 |
| Down Beta | -2.40 | -3.63 | -0.07 | 0.67 | 1.66 | 1.35 |
| Up Capture | 83% | 106% | 250% | 490% | 649% | 907% |
| Bmk +ve Days | 13 | 28 | 36 | 67 | 141 | 432 |
| Stock +ve Days | 13 | 26 | 35 | 68 | 132 | 366 |
| Down Capture | 85% | 241% | 272% | 207% | 178% | 114% |
| Bmk -ve Days | 7 | 13 | 27 | 57 | 109 | 318 |
| Stock -ve Days | 7 | 15 | 28 | 56 | 116 | 383 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with NTLA | |
|---|---|---|---|---|
| NTLA | 81.4% | 99.2% | 1.08 | - |
| Sector ETF (XLV) | 21.4% | 15.4% | 1.06 | 22.7% |
| Equity (SPY) | 22.2% | 12.5% | 1.32 | 30.2% |
| Gold (GLD) | 20.2% | 27.8% | 0.65 | 27.6% |
| Commodities (DBC) | 21.3% | 18.6% | 0.90 | -1.1% |
| Real Estate (VNQ) | 15.6% | 13.6% | 0.82 | 11.9% |
| Bitcoin (BTCUSD) | -44.0% | 42.6% | -1.25 | 24.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with NTLA | |
|---|---|---|---|---|
| NTLA | -26.2% | 81.3% | -0.01 | - |
| Sector ETF (XLV) | 6.8% | 14.8% | 0.28 | 31.8% |
| Equity (SPY) | 13.5% | 17.1% | 0.61 | 41.0% |
| Gold (GLD) | 17.2% | 18.3% | 0.76 | 11.5% |
| Commodities (DBC) | 7.1% | 19.5% | 0.26 | 3.3% |
| Real Estate (VNQ) | 2.9% | 18.8% | 0.05 | 32.7% |
| Bitcoin (BTCUSD) | 13.6% | 53.8% | 0.44 | 27.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with NTLA | |
|---|---|---|---|---|
| NTLA | -4.3% | 78.7% | 0.30 | - |
| Sector ETF (XLV) | 10.5% | 16.6% | 0.52 | 35.8% |
| Equity (SPY) | 15.4% | 18.0% | 0.73 | 41.1% |
| Gold (GLD) | 11.5% | 16.1% | 0.58 | 8.5% |
| Commodities (DBC) | 5.7% | 18.0% | 0.24 | 11.1% |
| Real Estate (VNQ) | 5.6% | 20.7% | 0.23 | 27.4% |
| Bitcoin (BTCUSD) | 55.0% | 66.4% | 0.95 | 19.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Updated 6/12/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/11/2026 | 2.3% | -3.0% | -8.5% |
| 2/26/2026 | 6.4% | 3.0% | -1.3% |
| 11/6/2025 | -22.7% | -29.6% | -24.5% |
| 8/7/2025 | 0.8% | -3.3% | 6.1% |
| 5/8/2025 | 13.6% | 8.1% | 11.0% |
| 2/27/2025 | 0.6% | -13.3% | -22.2% |
| 1/10/2025 | -15.1% | -21.6% | -20.3% |
| 11/7/2024 | -0.4% | 0.3% | -8.3% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 17 | 14 | 10 |
| # Negative | 12 | 15 | 19 |
| Median Positive | 4.8% | 6.8% | 6.1% |
| Median Negative | -7.8% | -6.7% | -8.5% |
| Max Positive | 16.1% | 22.0% | 59.9% |
| Max Negative | -22.7% | -29.6% | -25.7% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/11/2026 | 2.3% | -3.0% | -8.5% |
| 2/26/2026 | 6.4% | 3.0% | -1.3% |
| 11/6/2025 | -22.7% | -29.6% | -24.5% |
| 8/7/2025 | 0.8% | -3.3% | 6.1% |
| 5/8/2025 | 13.6% | 8.1% | 11.0% |
| 2/27/2025 | 0.6% | -13.3% | -22.2% |
| 1/10/2025 | -15.1% | -21.6% | -20.3% |
| 11/7/2024 | -0.4% | 0.3% | -8.3% |
| 8/8/2024 | 5.0% | 0.9% | -7.5% |
| 5/9/2024 | 8.1% | 14.0% | -1.2% |
| 2/22/2024 | 1.1% | 22.0% | 2.9% |
| 1/4/2024 | -3.0% | -4.6% | -15.9% |
| 11/9/2023 | -12.3% | -6.6% | 2.0% |
| 8/3/2023 | -1.6% | 0.8% | -5.6% |
| 5/4/2023 | 13.1% | 17.1% | 6.2% |
| 2/23/2023 | 0.1% | 4.6% | -4.5% |
| 1/5/2023 | -0.9% | -4.1% | 10.5% |
| 11/3/2022 | 1.0% | -5.5% | -9.7% |
| 8/4/2022 | -8.7% | -7.2% | -16.4% |
| 5/5/2022 | -10.2% | -28.3% | -18.7% |
| 2/24/2022 | 9.3% | 5.4% | -10.0% |
| 1/6/2022 | 1.2% | -5.2% | -7.2% |
| 11/4/2021 | -1.4% | -6.7% | -25.7% |
| 8/5/2021 | 12.4% | 8.7% | 18.4% |
| 5/6/2021 | -6.8% | -10.3% | 1.2% |
| 2/25/2021 | -9.8% | -9.4% | -0.4% |
| 1/7/2021 | 16.1% | 13.9% | 3.7% |
| 11/5/2020 | 4.8% | 9.1% | 59.9% |
| 8/6/2020 | 1.7% | 3.9% | -6.3% |
| SUMMARY STATS | |||
| # Positive | 17 | 14 | 10 |
| # Negative | 12 | 15 | 19 |
| Median Positive | 4.8% | 6.8% | 6.1% |
| Median Negative | -7.8% | -6.7% | -8.5% |
| Max Positive | 16.1% | 22.0% | 59.9% |
| Max Negative | -22.7% | -29.6% | -25.7% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/11/2026 | 10-Q |
| 12/31/2025 | 02/26/2026 | 10-K |
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 08/07/2025 | 10-Q |
| 03/31/2025 | 05/08/2025 | 10-Q |
| 12/31/2024 | 02/27/2025 | 10-K |
| 09/30/2024 | 11/07/2024 | 10-Q |
| 06/30/2024 | 08/08/2024 | 10-Q |
| 03/31/2024 | 05/09/2024 | 10-Q |
| 12/31/2023 | 02/22/2024 | 10-K |
| 09/30/2023 | 11/09/2023 | 10-Q |
| 06/30/2023 | 08/03/2023 | 10-Q |
| 03/31/2023 | 05/04/2023 | 10-Q |
| 12/31/2022 | 02/23/2023 | 10-K |
| 09/30/2022 | 11/03/2022 | 10-Q |
| 06/30/2022 | 08/04/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/11/2026 | 10-Q |
| 12/31/2025 | 02/26/2026 | 10-K |
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 08/07/2025 | 10-Q |
| 03/31/2025 | 05/08/2025 | 10-Q |
| 12/31/2024 | 02/27/2025 | 10-K |
| 09/30/2024 | 11/07/2024 | 10-Q |
| 06/30/2024 | 08/08/2024 | 10-Q |
| 03/31/2024 | 05/09/2024 | 10-Q |
| 12/31/2023 | 02/22/2024 | 10-K |
| 09/30/2023 | 11/09/2023 | 10-Q |
| 06/30/2023 | 08/03/2023 | 10-Q |
| 03/31/2023 | 05/04/2023 | 10-Q |
| 12/31/2022 | 02/23/2023 | 10-K |
| 09/30/2022 | 11/03/2022 | 10-Q |
| 06/30/2022 | 08/04/2022 | 10-Q |
| 03/31/2022 | 05/05/2022 | 10-Q |
| 12/31/2021 | 02/24/2022 | 10-K |
| 09/30/2021 | 11/04/2021 | 10-Q |
| 06/30/2021 | 08/05/2021 | 10-Q |
| 03/31/2021 | 05/06/2021 | 10-Q |
| 12/31/2020 | 02/26/2021 | 10-K |
| 09/30/2020 | 11/05/2020 | 10-Q |
| 06/30/2020 | 08/06/2020 | 10-Q |
| 03/31/2020 | 05/07/2020 | 10-Q |
| 12/31/2019 | 02/27/2020 | 10-K |
| 09/30/2019 | 10/31/2019 | 10-Q |
| 06/30/2019 | 08/01/2019 | 10-Q |
Insider Activity
Updated 6/10/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Basta, James | EVP, General Counsel | Direct | Sell | 3032026 | 13.78 | 1,211 | 16,688 | 2,160,621 | Form |
| 2 | Clark, Eliana | EVP, Chief Technical Officer | Direct | Sell | 3032026 | 13.78 | 607 | 8,364 | 1,293,446 | Form |
| 3 | Leonard, John M | President and CEO | Direct | Sell | 12122025 | 9.49 | 88,146 | 836,384 | 9,857,999 | Form |
| 4 | Schultes, Birgit C | EVP, Chief Scientific Officer | Direct | Sell | 10032025 | 17.38 | 31 | 539 | 1,828,098 | Form |
| 5 | Dube, Michael P | VP, Chief Accounting Officer | Direct | Sell | 10032025 | 17.38 | 1,871 | 32,518 | 960,523 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Basta, James | EVP, General Counsel | Direct | Sell | 3032026 | 13.78 | 1,211 | 16,688 | 2,160,621 | Form |
| 2 | Clark, Eliana | EVP, Chief Technical Officer | Direct | Sell | 3032026 | 13.78 | 607 | 8,364 | 1,293,446 | Form |
| 3 | Leonard, John M | President and CEO | Direct | Sell | 12122025 | 9.49 | 88,146 | 836,384 | 9,857,999 | Form |
| 4 | Schultes, Birgit C | EVP, Chief Scientific Officer | Direct | Sell | 10032025 | 17.38 | 31 | 539 | 1,828,098 | Form |
| 5 | Dube, Michael P | VP, Chief Accounting Officer | Direct | Sell | 10032025 | 17.38 | 1,871 | 32,518 | 960,523 | Form |
| 6 | Chase, William J | Direct | Buy | 8222025 | 10.03 | 100,000 | 1,003,000 | 1,350,971 | Form | |
| 7 | Dulac, Edward J Iii | EVP, Chief Financial Officer | Direct | Sell | 7252025 | 14.02 | 7,462 | 104,617 | 1,486,989 | Form |
| 8 | Dube, Michael P | VP, Chief Accounting Officer | Direct | Sell | 7032025 | 9.95 | 2,503 | 24,905 | 568,513 | Form |
| 9 | Clark, Eliana | EVP, Chief Technical Officer | Direct | Sell | 7032025 | 9.82 | 1,022 | 10,036 | 936,524 | Form |
| 10 | Goodman, Jesse | Direct | Sell | 7022025 | 9.23 | 1,547 | 14,279 | 224,834 | Form | |
| 11 | Goodman, Jesse | Direct | Sell | 7022025 | 9.56 | 1,547 | 14,789 | 247,661 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.